Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa
Pseudomonas aeruginosa : is one of the predominant pathogens associated with cystic fibrosis (CF) airway infections. Treatment is often challenging due to its intrinsic multidrug resistance, particularly because of the activity of tripartite resistance–nodulation–division (RND) drug efflux pumps such as the MexAB–OprM system. We have previously shown that ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used in CF therapy, could enhance antibiotic activity against Escherichia coli through inhibition of the AcrB drug efflux protein. Given the high level of homology between the resistance-nodulation-division (RND) transporters from the drug efflux complexes, AcrB and MexB, the aim of this study was to investigate if ivacaftor could also synergise with antibiotics used to treat Pseudomonas aeruginosa infections in people with cystic fibrosis. Molecular dynamics simulation interrogated the interaction between ivacaftor and MexB. Thermal shift analysis and surface plasmon resonance were employed to determine the affinity of ivacaftor binding to MexB. The effects of ivacaftor on antibiotic susceptibility, efflux activity, and membrane integrity were investigated for reference strains and clinical P. aeruginosa strains isolated from people with CF. Our results predicted binding of ivacaftor to the distal binding site of MexB. Ivacaftor interacted with the RND transporters AcrB and MexB with a similar affinity as the efflux pump inhibitor (EPI) phenylalanine-arginine beta-naphthylamide (PAβN). Checkerboard assays demonstrated that ivacaftor restored susceptibility to several antibiotics currently used in anti-pseudomonal CF therapy, particularly aztreonam, ceftazidime, ciprofloxacin, and meropenem, while enhancing the antibiotic activity of azithromycin, erythromycin and minocycline. Nile Red efflux and Hoechst 33342 accumulation assays further supported inhibition of efflux activity by ivacaftor. Ivacaftor did not produce any off-target effects on the bacterial inner- or outer membrane. Overall, the results suggest that ivacaftor can function as an EPI in P. aeruginosa, thereby enhancing antibiotic activity. These findings support further investigation of CFTR modulators as adjunctive therapies against chronic infections caused by multidrug-resistant P. aeruginosa.
Authors
- Steven W. Polyak (ORCID: https://orcid.org/0000-0002-8458-5194)
- Henrietta Venter (ORCID: https://orcid.org/0000-0001-5569-7755)
- Utid Suriya (ORCID: https://orcid.org/0000-0001-7742-8249)
- Susan J. Semple (ORCID: https://orcid.org/0000-0001-5988-3993)
- Matthew Phanchana (ORCID: https://orcid.org/0000-0002-7736-7500)
- Sylvia A. Sapula (ORCID: https://orcid.org/0000-0002-5534-9774)
- Yang Chen (ORCID: https://orcid.org/0000-0002-9772-8692)
- Judith M. Morton (ORCID: https://orcid.org/0000-0002-1715-5573)
- Hanbiao Chen
- Sida Liu
Institutions
- Royal Adelaide Hospital (AU)
- Mahidol University (TH)
- Adelaide University (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fphar.2026.1979931
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council